Journal Article

DKFZ-2020-01711

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Diagnostic accuracy of 18F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence.

Sprute, K. ; Kramer, V. ; Koerber, S. ; Meneses, M. ; Fernandez, R. ; Soza-Ried, C. ; Eiber, M. ; Weber, W. ; Rauscher, I. ; Rahbar, K. ; Schaefers, M. ; Watabe, T. ; Uemura, M. ; Naka, S. ; Nonomura, N. ; Hatazawa, J. ; Schwab, C. ; Schütz, V. ; Hohenfellner, M. ; Holland-Letz, T.DKFZ* ; Debus, J. ; Kratochwil, C. ; Amaral, H. ; Choyke, P. L. ; Haberkorn, U. ; Sandoval, C. ; Giesel, F. L.

2021
Soc. New York, NY

This record in other databases:  

Please use a persistent id in citations: doi:10.2967/jnumed.120.246363

Abstract: Purpose: Prostate specific membrane antigen (PSMA) -ligand PET/CT is performed in patients with prostate cancer to stage the disease initially or to identify sites of recurrence after definitive therapy. 18F-PSMA-1007 is a promising PSMA-PET tracer based on clinical results, but detailed histologic confirmation has been lacking. Experimental Design: 96 patients with prostate cancer received a 18F-PSMA-1007-PET/CT followed by either radical prostatectomy with lymphadenectomy or salvage lymphadenectomy. The histological findings of PSMA-PET-positive nodes were analysed retrospectively. A lesion and a patient-based analysis was performed comparing 1) all positive and 2) only lesions with a size larger than 3 mm in histopathology. Results: 90.6% of the patients received 18F-PSMA-1007-PET/CT for staging before the primary treatment, while 9.4 % of the cohort underwent imaging for biochemical recurrence. In 34.4% of the cohort positive lymph nodes were present in imaging. A total of 1746 lymph nodes were dissected in 96 patients. 18F-PSMA-1007-PET had a lesion-based sensitivity of 81.7% a specificity of 99.6%, a positive predictive value (PPV) of 92.4%, a negative predictive value (NPV) of 98.9% for detecting positive lymph nodes larger than 3 mm. In the analysis of all malignant nodes regardless the size the overall sensitivity, specificity, PPV, and NPV on lesion-based analysis was 71.2%, 99.5%, 91.3%, and 97.9%, respectively. The patient-based analysis showed a sensitivity of 85.9% and a specificity of 99.5% for lymph nodes >3 mm. Conclusion:18F-PSMA-1007-PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of >99% for nodal metastases.

Note: 2021 Feb;62(2):208-213

---

Contributing Institute(s):

1. C060 Biostatistik (C060)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2021

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---